Loading candles…
Zim Laboratories Ltd, incorporated in 1989 and headquartered in India, operates in the pharmaceutical and nutraceutical industries. The company manufactures formulation drugs and pre-formulation ingredients, focusing on differentiated and complex generic products. Its offerings include oral solid dosage forms, Novel Drug Delivery Systems (NDDS), Pre-Formulation Intermediates (PFI), and Finished Formulations (FF). Zim Laboratories markets and sells its products both within India and internationally, covering regulated, pharmerging, and other global markets. The company emphasizes development and manufacturing using proprietary technologies to serve the pharmaceutical and nutraceutical sectors.
This page is a live market overview for ZIM LABORATORIES LIMITED (ZIMLAB) on the NSE. As a listed security, ZIM LABORATORIES LIMITED is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for ZIMLAB before placing trades on tick2trade.
As of the latest feed, ZIMLAB last traded at ₹132.23 on NSE, down ₹1.57 (1.17%) from the previous close of ₹133.8. Today's session range is ₹130.75 – ₹135.8, against a 52-week band of ₹59.31 – ₹144.49. Traded volume today stands at 47.86K shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for ZIMLAB in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether ZIMLAB is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for ZIM LABORATORIES LIMITED before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in ZIMLAB. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated ZIMLAB option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | To consider and approve the financial results for the period ended Jun 30, 2026 | 6 Aug 2026 |
| Results - FY26 | To consider and approve the financial results for the period ended March 31, 2026 | 19 May 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended December 31, 2025 | 11 Feb 2026 |
| Fund Raising | To consider Fund Raising | 21 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 12 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 7 Aug 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended March 31, 2025 | 20 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.